Alkermes plc. — Director's Dealing 2024

Jun 4, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2024-05-31

Reporting Person: Wright Christopher I (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-17	Non Qualified Stock Option (Right to Buy)	$28.40	J	14	Acquired	2032-06-08	Ordinary Shares (14)	Direct
2023-11-17	Non Qualified Stock Option (Right to Buy)	$28.40	J	355	Acquired	2032-06-08	Ordinary Shares (355)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	129	Acquired		Ordinary Shares (129)	Direct
2023-11-17	Non Qualified Stock Option (Right to Buy)	$30.86	J	231	Acquired	2032-07-07	Ordinary Shares (231)	Direct
2023-11-17	Non Qualified Stock Option (Right to Buy)	$30.72	J	254	Acquired	2033-06-29	Ordinary Shares (254)	Direct
2023-11-17	Restricted Stock Unit Award	$	J	119	Acquired		Ordinary Shares (119)	Direct
2024-05-31	Restricted Stock Unit Award	$	A	8013	Acquired		Ordinary Shares (8013)	Direct
2024-05-31	Non Qualified Stock Option (Right to Buy)	$23.40	A	17492	Acquired	2034-05-31	Ordinary Shares (17492)	Direct

Footnotes

F1: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F2: These options are fully vested in accordance with their terms.

F3: Shares subject to the stock option award vest in three equal annual installments commencing on 6/8/2023.

F4: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023.

F6: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.

F7: Shares subject to the restricted stock unit award vest in full on 6/29/2024.

F8: Shares subject to the restricted stock unit award vest in full on 5/31/2025.

F9: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025.